A heat shock protein 70-based vaccine with enhanced immunogenicity for clinical use

Journal of Immunology

Volumn 184, Issue 1, 2010, Pages 488-496

  Gong, Jianlin ^a   Zhang, Yunfei ^a   Durfee, John ^b   Weng, Desheng ^a   Liu, Chunlei ^a   Koido, Shigeo ^d   Song, Baizheng ^a   Apostolopoulos, Vasso ^e   Calderwood, Stuart K ^c  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON MEDICAL CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e BURNET INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; GAMMA INTERFERON; HEAT SHOCK PROTEIN 110; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; TUMOR ANTIGEN; HEAT SHOCK PROTEIN 72;

ARTICLE; BREAST CANCER; CANCER CELL; CELL FUSION; CELL KILLING; CONTROLLED STUDY; DENDRITIC CELL; DRUG FORMULATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOGENICITY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN ISOLATION; ACTIVE IMMUNIZATION; BIOSYNTHESIS; CELL PROLIFERATION; CONFOCAL MICROSCOPY; CYTOTOXICITY; IMMUNOBLOTTING; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METHODOLOGY; T LYMPHOCYTE; TUMOR CELL LINE;

ANTIGENS, NEOPLASM; CANCER VACCINES; CELL FUSION; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FEMALE; HSP72 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOBLOTTING; IMMUNOTHERAPY, ACTIVE; LYMPHOCYTE ACTIVATION; MICROSCOPY, CONFOCAL; T-LYMPHOCYTES;

EID: 73949095492     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0902255     Document Type: Article

References (34)

1. Lindquist, S., and E. A. Craig. 1988. The heat-shock proteins. Annu. Rev. Genet. 22: 631-677.
2. Wegele, H., L. Müller, and J. Buchner. 2004. Hsp70 and Hsp90 - a relay team for protein folding. Rev. Physiol. Biochem. Pharmacol. 151: 1-44.
3. Young, J. C., V. R. Agashe, K. Siegers, and F. U. Hartl. 2004. Pathways of chaperone-mediated protein folding in the cytosol. Nat. Rev. Mol. Cell Biol. 5: 781-791.
4. Murshid, A., J. Gong, and S. K. Calderwood. 2008. Heat-shock proteins in cancer vaccines: agents of antigen cross-presentation. Expert Rev. Vaccines 7: 1019-1030.
5. Srivastava, P. K. 2005. Immunotherapy for human cancer using heat shock protein-peptide complexes. Curr. Oncol. Rep. 7: 104-108.
6. Srivastava, P. K., A. B. DeLeo, and L. J. Old. 1986. Tumor rejection antigens of chemically induced sarcomas of inbred mice. Proc. Natl. Acad. Sci. U.S.A. 83: 3407-3411.
7. Udono, H., D. L. Levey, and P. K. Srivastava. 1994. Cellular requirements for tumor-specific immunity elicited by heat shock proteins: tumor rejection antigen gp96 primes CD8+ T cells in vivo. Proc. Natl. Acad. Sci. USA 91: 3077-3081.
8. Blachere, N. E., H. Udono, S. Janetzki, Z. Li, M. Heike, and P. K. Srivastava. 1993. Heat shock protein vaccines against cancer. J. Immunother. Emphasis Tumor Immunol. 14: 352-356.
9. Vanaja, D. K., M. E. Grossmann, E. Celis, and C. Y. Young. 2000. Tumor prevention and antitumor immunity with heat shock protein 70 induced by 15-deoxy-delta12, 14-prostaglandin J2 in transgenic adenocarcinoma of mouse prostate cells. Cancer Res. 60: 4714-4718.
10. Tamura, Y., P. Peng, K. Liu, M. Daou, and P. K. Srivastava. 1997. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 278: 117-120.
11. Kovalchin, J. T., A. S. Murthy, M. C. Horattas, D. P. Guyton, and R. Y. Chandawarkar. 2001. Determinants of efficacy of immunotherapy with tumor-derived heat shock protein gp96. Cancer Immun. 1: 7.
12. Belli, F., A. Testori, L. Rivoltini, M. Maio, G. Andreola, M. R. Sertoli, G. Gallino, A. Piris, A. Cattelan, I. Lazzari, et al. 2002. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J. Clin. Oncol. 20: 4169-4180.
13. Pilla, L., R. Patuzzo, L. Rivoltini, M. Maio, E. Pennacchioli, E. Lamaj, A. Maurichi, S. Massarut, A. Marchianò, C. Santantonio, et al. 2006. A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-a in metastatic melanoma patients. Cancer Immunol. Immunother. 55: 958-968.
14. Testori, A., J. Richards, E. Whitman, G. B. Mann, J. Lutzky, L. Camacho, G. Parmiani, G. Tosti, J. M. Kirkwood, A. Hoos, et al. 2008. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J. Clin. Oncol. 26: 955-962.
15. Mazzaferro, V., J. Coppa, M. G. Carrabba, L. Rivoltini, M. Schiavo, E. Regalia, L. Mariani, T. Camerini, A. Marchianò, S. Andreola, et al. 2003. Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin. Cancer Res. 9: 3235-3245.
16. Wood, C., P. Srivastava, R. Bukowski, L. Lacombe, A. I. Gorelov, S. Gorelov, P. Mulders, H. Zielinski, A. Hoos, F. Teofilovici, et al. 2008. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 372: 145-154.
17. Enomoto, Y., A. Bharti, A. A. Khaleque, B. Song, C. Liu, V. Apostolopoulos, P. X. Xing, S. K. Calderwood, and J. Gong. 2006. Enhanced immunogenicity of heat shock protein 70 peptide complexes from dendritic cell-tumor fusion cells. J. Immunol. 177: 5946-5955.
18. Koido, S., N. Nikrui, M. Ohana, J. Xia, Y. Tanaka, C. Liu, J. K. Durfee, A. Lerner, and J. Gong. 2005. Assessment of fusion cells from patient-derived ovarian carcinoma cells and dendritic cells as a vaccine for clinical use. Gynecol. Oncol. 99: 462-471.
19. Stevenson, M. A., and S. K. Calderwood. 1990. Members of the 70-kilodalton heat shock protein family contain a highly conserved calmodulin-binding domain. Mol. Cell. Biol. 10: 1234-1238.
20. Apostolopoulos, V., G. Chelvanayagam, P. X. Xing, and I. F. McKenzie. 1998. Anti-MUC1 antibodies react directly with MUC1 peptides presented by class I H2 and HLA molecules. J. Immunol. 161: 767-775. (Pubitemid 28323540)
21. Calderwood, S. K., J. R. Theriault, and J. Gong. 2005. Message in a bottle: role of the 70-kDa heat shock protein family in anti-tumor immunity. Eur. J. Immunol. 35: 2518-2527.
22. Udono, H., and P. K. Srivastava. 1993. Heat shock protein 70-associated peptides elicit specific cancer immunity. J. Exp. Med. 178: 1391-1396.
23. Arnold, D., S. Faath, H. Rammensee, and H. Schild. 1995. Cross-priming of minor histocompatibility antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96. J. Exp. Med. 182: 885-889.
24. Castelli, C., A. M. Ciupitu, F. Rini, L. Rivoltini, A. Mazzocchi, R. Kiessling, and G. Parmiani. 2001. Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells. Cancer Res. 61: 222-227.
25. Huang, C., H. Yu, Q. Wang, W. Ma, D. Xia, P. Yi, L. Zhang, and X. Cao. 2004. Potent antitumor effect elicited by superantigen-linked tumor cells transduced with heat shock protein 70 gene. Cancer Sci. 95: 160-167.
26. Mizukami, S., C. Kajiwara, H. Ishikawa, I. Katayama, K. Yui, and H. Udono. 2008. Both CD4+ and CD8+ T cell epitopes fused to heat shock cognate protein 70 (hsc70) can function to eradicate tumors. Cancer Sci. 99: 1008-1015.
27. Ueda, G., Y. Tamura, I. Hirai, K. Kamiguchi, S. Ichimiya, T. Torigoe, H. Hiratsuka, H. Sunakawa, and N. Sato. 2004. Tumor-derived heat shock protein 70-pulsed dendritic cells elicit tumor-specific cytotoxic T lymphocytes (CTLs) and tumor immunity. Cancer Sci. 95: 248-253.
28. Wang, X.Y., L.Kazim, E.A. Repasky, and J. R. Subjeck. 2003. Immunizationwith tumor-derived ER chaperone grp170 elicits tumor-specific CD8+ T-cell responses and reduces pulmonary metastatic disease. Int. J. Cancer 105: 226-231.
29. Sato, K., Y. Torimoto, Y. Tamura, M. Shindo, H. Shinzaki, K. Hirai, and Y. Kohgo. 2001. Immunotherapy using heat-shock protein preparations of leukemia cells after syngeneic bone marrow transplantation in mice. Blood 98: 1852-1857.
30. Blachere, N. E., Z. Li, R. Y. Chandawarkar, R. Suto, N. S. Jaikaria, S. Basu, H. Udono, and P. K. Srivastava. 1997. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. J. Exp. Med. 186: 1315-1322.
31. Binder, R. J., and P. K. Srivastava. 2005. Peptides chaperoned by heat-shock proteins are a necessary and sufficient source of antigen in the cross-priming of CD8+ T cells. Nat. Immunol. 6: 593-599.
32. Parmiani, G., A. De Filippo, L. Pilla, C. Castelli, and L. Rivoltini. 2006. Heat shock proteins gp96 as immunogens in cancer patients. Int. J. Hyperthermia 22: 223-227.
33. Oki, Y., P. McLaughlin, L. E. Fayad, B. Pro, P. F. Mansfield, G. L. Clayman, L. J. Medeiros, L. W. Kwak, P. K. Srivastava, and A. Younes. 2007. Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma. Cancer 109: 77-83.
34. Maki, R. G., P. O. Livingston, J. J. Lewis, S. Janetzki, D. Klimstra, D. Desantis, P. K. Srivastava, and M. F. Brennan. 2007. A phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma. Dig. Dis. Sci. 52: 1964-1972.